ACRV

Acrivon Therapeutics Stock Analysis

AI Rating

Neutral
  • Quality4/10
  • Growth↓ 3/10
  • Value↓ 4/10
Acrivon Therapeutics sales and earnings growth
ACRV Growth
Neutral
  • Revenue Y/Y↓ 0.00%
  • EPS Y/Y↑ 15.13%
  • FCF Y/Y↓ 4.53%
Acrivon Therapeutics gross and profit margin trends
ACRV Profitability
Low
  • Gross margin ↓ 0.00%
  • EPS margin↓ 0.00%
  • ROIC 5Y↓ -55.72%
Acrivon Therapeutics net debt vs free cash flow
ACRV Risk
Great
  • Debt / Equity↓ 0.0
  • Debt / FCF↓ 0.0
  • Interest coverage↑ 999.0

Acrivon Therapeutics stock volatility is higher than the overall market. We give it a Great risk rating.

More Biotechnology stocks ↗